Revised Terminology on Sepsis
Over recent years, major advances have been made in our understanding of the sepsis response, its origins, mediators, effects, and consequences. Ongoing research continues to add to our knowledge of this complex and complicated process. Sepsis is the systemic response to infection, but as it emerged that the inflammatory response which is aroused in sepsis can also occur in conditions in which infection is not apparent, attempts were made to introduce new terminology to define and label these conditions. Terms such as the sepsis syndrome  and the systemic inflammatory response syndrome (SIRS)  became popular and have been used widely in describing patients both individually and in larger groups for clinical trial purposes.
KeywordsSystemic Inflammatory Response Syndrome Septic Patient Meningococcal Disease Sepsis Syndrome Systemic Inflammatory Response Syndrome Criterion
Unable to display preview. Download preview PDF.
- 2.Anonymous (1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874Google Scholar
- 18.Nijsten MWN, Olinga P, The TH (1999) Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med (in press)Google Scholar
- 23.Müller B, Becker KL, Schächinger H et al (1999) Procalcitonin peptides are reliable markers of sepsis in a medical intensive care unit. Crit Care Med (in press)Google Scholar
- 30.Vincent JL (1999) Procalcitonin: the marker of sepsis? Crit Care Med (in press)Google Scholar
- 31.Opal SM, Fisher CJJ, Dhainaut JF et al (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25:1115–1124PubMedCrossRefGoogle Scholar
- 33.Dhainaut JF, Tenaillon A, Hemmer M et al (1998) Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 26:1963–1971PubMedCrossRefGoogle Scholar
- 36.Vincent JL (1999) The immune response in critical illness: Excessive, inadequate or dysregulated. In: Marshall JC, Cohen J (eds) Immune Response in the Critically Ill. Springer, Heidelberg, pp 12–21Google Scholar